Aconitum Napellus Whole Black Cohosh Camphor Datur

證據等級: L5

預測適應症: 0 個

Multi-Ingredient Homeopathic Formulation: Insufficient Evidence for Repurposing Evaluation

One-Sentence Summary

This candidate is a complex 20-ingredient formulation that appears to be a homeopathic or anthroposophic preparation combining neurotransmitters (dopamine, serotonin, epinephrine), classic homeopathic constituents (Lachesis muta venom, Lycosa tarantula, Pulsatilla pratensis, Ignatia), and conventional agents (lithium carbonate, thyroid extract, zinc). No approved indication, no DrugBank identifier, and no TxGNN-predicted new indication could be established from available data, making a formal repurposing evaluation impossible at this stage.

Quick Overview

Item	Content
Original Indication	No approved indication on record
Predicted New Indication	None — TxGNN produced no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (Model prediction only — and no prediction exists)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why This Evaluation Cannot Proceed

This formulation presents three fundamental barriers that prevent meaningful repurposing analysis:

1. Identity and Regulatory Status The candidate has no DrugBank ID, no brand name, no INN-level single-entity identity, and zero regulatory licenses worldwide (as captured in this dataset). Without a recognisable drug identity, neither knowledge-graph nor deep-learning TxGNN modules can anchor predictions. The result is an empty predicted_indications array.

2. Mechanistic Complexity The 20 listed ingredients span wildly different pharmacological classes — catecholamines (epinephrine, dopamine), a classical mood stabiliser (lithium carbonate), anticholinergic plant alkaloids (Datura stramonium, Hyoscyamus niger), venoms (Lachesis muta, Lycosa tarantula), and hormonal material (thyroid extract, Sus scrofa hypothalamus). In a homeopathic or anthroposophic context these are typically present at ultra-low dilutions, meaning their conventional pharmacological mechanisms may be irrelevant. No MOA data was retrievable.

3. No Predicted Indications Because TxGNN requires a resolvable drug node in the knowledge graph, the pipeline generated zero predictions. Without a target disease, no clinical trial search, literature review, or mechanistic bridge analysis was possible.

Conclusion and Next Steps

Decision: Hold

Rationale: The formulation cannot be evaluated for repurposing in its current form — it lacks a unique drug identity (no DrugBank ID), has no approved indication to anchor a “from → to” repurposing narrative, and produced no TxGNN predictions.

To proceed, the following is needed:

Resolve drug identity: Determine whether this is a registered homeopathic/anthroposophic product (e.g., a Heel Compositum or similar) and obtain its brand name, manufacturer, and any pharmacopoeia monograph reference.
Obtain a DrugBank ID or equivalent: Without a machine-readable identifier, TxGNN cannot generate predictions. Consider querying each ingredient individually.
Clarify regulatory history: Search TFDA, EMA, and FDA homeopathic drug databases for any historical registration or exemption status.
Define active ingredient scope: Confirm intended dilution levels (homeopathic vs. pharmacological doses) to determine which mechanistic framework (conventional pharmacology vs. homeopathic provings) applies.
Re-run TxGNN per ingredient: If the combination cannot be resolved as a single entity, run predictions separately for ingredients with known DrugBank IDs (e.g., lithium carbonate DB00999, epinephrine DB00668, dopamine DB00988, zinc DB09130) and aggregate results.
Retrieve safety data: Download any available product insert (TFDA or manufacturer) to complete DG001 (warnings/contraindications) and DG002 (MOA).
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.